Discuss Abbott Laboratories
Abbott Laboratories
WKN: 850103 / Symbol: ABT / Name: Abbott / Aktie / Pharmazeutika / Large Cap /
88,50 €
0,77 %
Abbott Laboratories (NYSE:ABT) had its price target raised by analysts at Sanford C. Bernstein from $150.00 to $154.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $157.00 to $152.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Piper Sandler from $150.00 to $135.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at BTIG Research from $145.00 to $140.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Evercore ISI from $144.00 to $138.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Raymond James Financial, Inc. from $146.00 to $130.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $152.00 to $140.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $140.00 to $132.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Royal Bank Of Canada from $147.00 to $135.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Sanford C. Bernstein from $154.00 to $125.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Citigroup Inc. from $155.00 to $140.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) was upgraded by analysts at Freedom Capital from a "hold" rating to a "strong-buy" rating.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Daiwa Capital Markets from $136.00 to $113.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at Barclays PLC from $169.00 to $142.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE:ABT) had its price target lowered by analysts at BTIG Research from $145.00 to $140.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (ABT) had its price target lowered by Citigroup Inc. from $140.00 to $136.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (ABT) had its price target lowered by BTIG Research from $140.00 to $131.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (ABT) had its price target lowered by Evercore Inc from $138.00 to $134.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (ABT) had its price target lowered by The Goldman Sachs Group, Inc. from $140.00 to $121.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (ABT) had its price target raised by Barclays PLC from $142.00 to $144.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Neueste Beiträge
Wells_Fargo___Compan in EOG Resources Inc. diskutieren